St. Louis Trust Co maintained its position in Bristol-Myers Squibb Company (NYSE:BMY) during the 2nd quarter, according to its most recent filing with the SEC. The fund owned 33,096 shares of the biopharmaceutical company’s stock at the close of the 2nd quarter. Bristol-Myers Squibb makes up about 0.8% of St. Louis Trust Co’s holdings, making the stock its 19th biggest holding. St. Louis Trust Co’s holdings in Bristol-Myers Squibb were worth $1,844,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. State Street Corp increased its stake in shares of Bristol-Myers Squibb by 1.8% in the first quarter. State Street Corp now owns 68,893,779 shares of the biopharmaceutical company’s stock worth $3,746,446,000 after purchasing an additional 1,223,457 shares in the last quarter. Jennison Associates LLC increased its stake in shares of Bristol-Myers Squibb by 0.8% in the first quarter. Jennison Associates LLC now owns 21,927,898 shares of the biopharmaceutical company’s stock worth $1,192,439,000 after purchasing an additional 178,436 shares in the last quarter. Ameriprise Financial Inc. increased its stake in shares of Bristol-Myers Squibb by 18.7% in the first quarter. Ameriprise Financial Inc. now owns 15,547,051 shares of the biopharmaceutical company’s stock worth $845,504,000 after purchasing an additional 2,451,390 shares in the last quarter. Legal & General Group Plc increased its stake in shares of Bristol-Myers Squibb by 4.3% in the first quarter. Legal & General Group Plc now owns 8,213,428 shares of the biopharmaceutical company’s stock worth $446,664,000 after purchasing an additional 335,795 shares in the last quarter. Finally, Swiss National Bank increased its stake in shares of Bristol-Myers Squibb by 27.2% in the first quarter. Swiss National Bank now owns 5,921,670 shares of the biopharmaceutical company’s stock worth $322,020,000 after purchasing an additional 1,267,900 shares in the last quarter. Institutional investors and hedge funds own 68.87% of the company’s stock.

In other Bristol-Myers Squibb news, SVP Joseph C. Caldarella sold 9,340 shares of the stock in a transaction that occurred on Wednesday, September 6th. The shares were sold at an average price of $60.00, for a total transaction of $560,400.00. Following the completion of the sale, the senior vice president now directly owns 46,297 shares of the company’s stock, valued at approximately $2,777,820. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Theodore R. Samuels II acquired 6,000 shares of the business’s stock in a transaction on Wednesday, August 2nd. The shares were bought at an average cost of $55.94 per share, with a total value of $335,640.00. Following the completion of the acquisition, the director now owns 18,000 shares in the company, valued at $1,006,920. The disclosure for this purchase can be found here. Company insiders own 0.23% of the company’s stock.

Several equities analysts have recently weighed in on the stock. BidaskClub upgraded shares of Bristol-Myers Squibb from a “sell” rating to a “hold” rating in a research note on Saturday, August 12th. BMO Capital Markets set a $49.00 target price on shares of Bristol-Myers Squibb and gave the stock a “sell” rating in a research note on Thursday. Goldman Sachs Group, Inc. (The) reiterated a “buy” rating and issued a $63.00 target price on shares of Bristol-Myers Squibb in a research note on Wednesday, August 9th. Jefferies Group LLC reiterated a “buy” rating and issued a $72.00 target price on shares of Bristol-Myers Squibb in a research note on Wednesday, September 27th. Finally, Vetr downgraded shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating and set a $63.67 target price for the company. in a research note on Thursday, September 28th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating and eleven have issued a buy rating to the company’s stock. Bristol-Myers Squibb currently has an average rating of “Buy” and a consensus target price of $62.71.

Shares of Bristol-Myers Squibb Company (NYSE BMY) opened at 65.35 on Friday. Bristol-Myers Squibb Company has a 12 month low of $46.01 and a 12 month high of $65.73. The company has a market capitalization of $107.17 billion, a price-to-earnings ratio of 23.87 and a beta of 1.19. The firm’s 50-day moving average is $62.45 and its 200 day moving average is $56.90.

Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported $0.74 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.73 by $0.01. Bristol-Myers Squibb had a net margin of 22.66% and a return on equity of 32.33%. The business had revenue of $5.14 billion during the quarter, compared to analyst estimates of $5.09 billion. During the same period last year, the firm posted $0.69 EPS. The company’s revenue was up 5.6% on a year-over-year basis. Equities analysts expect that Bristol-Myers Squibb Company will post $2.98 EPS for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, November 1st. Shareholders of record on Friday, October 6th will be issued a dividend of $0.39 per share. This represents a $1.56 dividend on an annualized basis and a yield of 2.39%. The ex-dividend date of this dividend is Thursday, October 5th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is currently 56.73%.

TRADEMARK VIOLATION NOTICE: This piece of content was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece of content on another site, it was stolen and republished in violation of U.S. and international copyright legislation. The legal version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/10/13/bristol-myers-squibb-company-bmy-holdings-held-by-st-louis-trust-co.html.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Company (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Stock Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related stocks with our FREE daily email newsletter.